Nova Eye Medical has announced an application to secure public funding for its iTrack ab-interno canaloplasty as a standalone minimally invasive glaucoma surgery (MIGS) procedure in Australia has formally progressing to the third and final stage of the assessment process. Read more
Glaukos has unveiled a new single-use surgical gonioscopy lens that is said to provide exceptional clarity with expanded views of angle structures. Read more
Medicinal cannabis is often presented as an alternative treatment for glaucoma. Although there is evidence that cannabis lowers intraocular pressure, its role as a viable glaucoma therapy is limited by a short duration of action, psychotropic effects, and possible tachyphylaxis.
A Victorian biopharmaceutical company has reported positive results from a Phase 1 study examining the safety of its biodegradable implant for glaucoma. Read more
A proposed merger between two pharmaceutical companies that compete in the glaucoma treatment markets has been given the green light – with one major stipulation. Read more
Adelaide ophthalmic device manufacturer Nova Eye Medical is developing a next generation iTrack glaucoma surgical system to reduce operating times. It is also progressing towards a pivotal US study for its 2RT laser therapy for intermediate AMD that could fulfil a distinct gap in a multi-billion-dollar market. Read more
The 2014 arrival of MIGS to Australia introduced a whole new field of interventional glaucoma therapies. Queensland ophthalmologist Dr Frank Howes re-defines the term and explores current surgical interventions, explaining where each fits in the glaucoma treatment algorithm. Read more
From this month, surgeons can perform standalone minimally invasive glaucoma surgery (MIGS) under Medicare, seeing Australia become the first major developed economy to universally approve the procedure in both public and private settings. Read more
Australian researchers have featured prominently in research efforts that have determined no genetic link between myopia and primary open-angle glaucoma (POAG). Read more
A world-first clinical trial in Australia is investigating whether vitamin B3 could help protect nerve cells against damage in glaucoma. Read more